JP2021502392A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502392A5 JP2021502392A5 JP2020526149A JP2020526149A JP2021502392A5 JP 2021502392 A5 JP2021502392 A5 JP 2021502392A5 JP 2020526149 A JP2020526149 A JP 2020526149A JP 2020526149 A JP2020526149 A JP 2020526149A JP 2021502392 A5 JP2021502392 A5 JP 2021502392A5
- Authority
- JP
- Japan
- Prior art keywords
- ataxia
- medicament according
- patient
- administered
- riluzole prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010003591 Ataxia Diseases 0.000 claims description 57
- 239000000651 prodrug Substances 0.000 claims description 27
- 229940002612 prodrug Drugs 0.000 claims description 27
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims description 25
- 229960004181 riluzole Drugs 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 6
- 230000004424 eye movement Effects 0.000 claims description 6
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 4
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 4
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 4
- 108091023045 Untranslated Region Proteins 0.000 claims description 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 102000014461 Ataxins Human genes 0.000 claims description 3
- 108010078286 Ataxins Proteins 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- 230000003205 diastolic effect Effects 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- 102000007372 Ataxin-1 Human genes 0.000 claims description 2
- 108010032963 Ataxin-1 Proteins 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 241000255925 Diptera Species 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 102000007371 Ataxin-3 Human genes 0.000 description 3
- 206010050389 Cerebral ataxia Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 208000004622 abetalipoproteinemia Diseases 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000003636 hereditary ataxia Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023149803A JP2023175823A (ja) | 2017-11-12 | 2023-09-15 | 運動失調を処置するためのリルゾールプロドラッグの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584856P | 2017-11-12 | 2017-11-12 | |
| US62/584,856 | 2017-11-12 | ||
| US201862717948P | 2018-08-13 | 2018-08-13 | |
| US62/717,948 | 2018-08-13 | ||
| PCT/US2018/060232 WO2019094851A1 (en) | 2017-11-12 | 2018-11-11 | Use of riluzole prodrugs to treat ataxias |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023149803A Division JP2023175823A (ja) | 2017-11-12 | 2023-09-15 | 運動失調を処置するためのリルゾールプロドラッグの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502392A JP2021502392A (ja) | 2021-01-28 |
| JP2021502392A5 true JP2021502392A5 (enExample) | 2021-10-21 |
| JP7352542B2 JP7352542B2 (ja) | 2023-09-28 |
Family
ID=66438598
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526149A Active JP7352542B2 (ja) | 2017-11-12 | 2018-11-11 | 運動失調を処置するためのリルゾールプロドラッグの使用 |
| JP2023149803A Pending JP2023175823A (ja) | 2017-11-12 | 2023-09-15 | 運動失調を処置するためのリルゾールプロドラッグの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023149803A Pending JP2023175823A (ja) | 2017-11-12 | 2023-09-15 | 運動失調を処置するためのリルゾールプロドラッグの使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20210023061A1 (enExample) |
| EP (2) | EP3706739B1 (enExample) |
| JP (2) | JP7352542B2 (enExample) |
| KR (2) | KR20200103658A (enExample) |
| CN (1) | CN112292127A (enExample) |
| AU (1) | AU2018364749C1 (enExample) |
| BR (1) | BR112020009173A2 (enExample) |
| CA (1) | CA3082096A1 (enExample) |
| DK (1) | DK3706739T3 (enExample) |
| ES (1) | ES2996892T3 (enExample) |
| FI (1) | FI3706739T3 (enExample) |
| HR (1) | HRP20241675T1 (enExample) |
| HU (1) | HUE070302T2 (enExample) |
| IL (1) | IL274532B2 (enExample) |
| LT (1) | LT3706739T (enExample) |
| MD (1) | MD3706739T2 (enExample) |
| MX (2) | MX2020004678A (enExample) |
| PH (1) | PH12020550583A1 (enExample) |
| PL (1) | PL3706739T3 (enExample) |
| PT (1) | PT3706739T (enExample) |
| RS (1) | RS66277B1 (enExample) |
| SG (1) | SG11202004332XA (enExample) |
| SI (1) | SI3706739T1 (enExample) |
| SM (1) | SMT202500022T1 (enExample) |
| WO (1) | WO2019094851A1 (enExample) |
| ZA (1) | ZA202002626B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62915B1 (sr) | 2015-03-03 | 2022-03-31 | Biohaven Therapeutics Ltd | Prolekovi riluzola i njihova primena |
| US12295942B2 (en) | 2015-03-03 | 2025-05-13 | Biohaven Therapeutics Ltd. | Riluzole prodrugs and their use |
| WO2018031707A1 (en) | 2016-08-10 | 2018-02-15 | Biohaven Pharmaceutical Holding Company Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
| WO2022155564A1 (en) * | 2021-01-18 | 2022-07-21 | Biohaven Therapeutics Ltd. | Use of riluzole prodrugs to treat alzheimer's disease |
| US20250129090A1 (en) * | 2021-11-04 | 2025-04-24 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| WO2023230451A2 (en) * | 2022-05-23 | 2023-11-30 | Biohaven Therapeutics Ltd. | Methods of treating spinocerebellar ataxias |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| WO1995001782A2 (en) | 1993-07-09 | 1995-01-19 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
| US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
| US5837287A (en) | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| DE69840495D1 (de) | 1997-02-20 | 2009-03-12 | Massachusetts Inst Technology | Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben |
| JP4947833B2 (ja) | 1997-07-25 | 2012-06-06 | アルペックス・ファルマ・ソシエテ・アノニム | 速崩壊性口内溶解錠の製造に適した顆粒の製造方法 |
| FR2774592B1 (fr) * | 1998-02-06 | 2000-03-17 | Rhone Poulenc Rorer Sa | Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet |
| US7939105B2 (en) | 1998-11-20 | 2011-05-10 | Jagotec Ag | Process for preparing a rapidly dispersing solid drug dosage form |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| EP1443912B1 (en) | 2001-10-12 | 2007-08-29 | Elan Pharma International Limited | Compositions having a combination of immediate release and controlled release characteristics |
| WO2003068604A1 (en) | 2002-02-13 | 2003-08-21 | Weibel Michael K | Drug dose-form and method of manufacture |
| DK1477166T3 (da) * | 2003-04-28 | 2006-12-11 | Biofrontera Bioscience Gmbh | Anvendelse af riluzoler kombineret med egnede hjælpe- og tilsætningsstoffer til behandling af sygdomme, som er kendetegnet ved en hyperproliferation af keratinocytter, navnlig neurodermitis og psoriasis |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| BRPI0620578A2 (pt) | 2005-12-27 | 2011-12-06 | Jubilant Organosys Ltd | composição farmacêutica que dissolve na boca e processo para o preparo da mesma |
| EP2170282A4 (en) | 2007-06-27 | 2014-11-05 | Hanmi Pharm Ind Co Ltd | METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION |
| JP2011516489A (ja) * | 2008-03-31 | 2011-05-26 | ユニバーシティ・オブ・サウス・フロリダ | 疾患誘発性運動失調症および非運動失調性平衡異常の治療法 |
| US8414356B2 (en) | 2008-10-31 | 2013-04-09 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| US8545806B2 (en) | 2008-10-31 | 2013-10-01 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| RS62915B1 (sr) * | 2015-03-03 | 2022-03-31 | Biohaven Therapeutics Ltd | Prolekovi riluzola i njihova primena |
-
2018
- 2018-11-11 IL IL274532A patent/IL274532B2/en unknown
- 2018-11-11 EP EP18876779.2A patent/EP3706739B1/en active Active
- 2018-11-11 CN CN201880073828.6A patent/CN112292127A/zh active Pending
- 2018-11-11 KR KR1020207016775A patent/KR20200103658A/ko not_active Ceased
- 2018-11-11 KR KR1020257006278A patent/KR20250034521A/ko active Pending
- 2018-11-11 SI SI201831180T patent/SI3706739T1/sl unknown
- 2018-11-11 WO PCT/US2018/060232 patent/WO2019094851A1/en not_active Ceased
- 2018-11-11 JP JP2020526149A patent/JP7352542B2/ja active Active
- 2018-11-11 MD MDE20200953T patent/MD3706739T2/ro unknown
- 2018-11-11 US US16/762,165 patent/US20210023061A1/en active Pending
- 2018-11-11 MX MX2020004678A patent/MX2020004678A/es unknown
- 2018-11-11 DK DK18876779.2T patent/DK3706739T3/da active
- 2018-11-11 LT LTEPPCT/US2018/060232T patent/LT3706739T/lt unknown
- 2018-11-11 SG SG11202004332XA patent/SG11202004332XA/en unknown
- 2018-11-11 HU HUE18876779A patent/HUE070302T2/hu unknown
- 2018-11-11 CA CA3082096A patent/CA3082096A1/en active Pending
- 2018-11-11 HR HRP20241675TT patent/HRP20241675T1/hr unknown
- 2018-11-11 RS RS20241371A patent/RS66277B1/sr unknown
- 2018-11-11 EP EP24199849.1A patent/EP4483956A3/en active Pending
- 2018-11-11 SM SM20250022T patent/SMT202500022T1/it unknown
- 2018-11-11 PT PT188767792T patent/PT3706739T/pt unknown
- 2018-11-11 BR BR112020009173-1A patent/BR112020009173A2/pt unknown
- 2018-11-11 FI FIEP18876779.2T patent/FI3706739T3/fi active
- 2018-11-11 AU AU2018364749A patent/AU2018364749C1/en active Active
- 2018-11-11 ES ES18876779T patent/ES2996892T3/es active Active
- 2018-11-11 PL PL18876779.2T patent/PL3706739T3/pl unknown
-
2020
- 2020-05-08 PH PH12020550583A patent/PH12020550583A1/en unknown
- 2020-05-11 ZA ZA2020/02626A patent/ZA202002626B/en unknown
- 2020-07-13 MX MX2023012640A patent/MX2023012640A/es unknown
-
2023
- 2023-07-17 US US18/353,840 patent/US12102618B2/en active Active
- 2023-07-17 US US18/353,850 patent/US20230355592A1/en active Pending
- 2023-09-15 JP JP2023149803A patent/JP2023175823A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502392A5 (enExample) | ||
| JP7650929B2 (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| Roberts | Onychomycosis: current treatment and future challenges | |
| CN108721265B (zh) | 通过给予秋水仙碱衍生物治疗或预防心血管事件 | |
| JP2015524444A5 (enExample) | ||
| US20100093754A1 (en) | Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual Disorders | |
| CN116712422A (zh) | 治疗特定患者群体的神经变性病症的方法 | |
| EP4520394A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2016074728A (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| JPWO2008090736A1 (ja) | アルツハイマー型認知症の予防及び治療のための医薬 | |
| JP2019507786A5 (enExample) | ||
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| ES2275619T3 (es) | Quetiapina para el tratamiento de discinesia en pacientes no psicoticos. | |
| ES2668943T3 (es) | Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz | |
| JPWO2020023324A5 (enExample) | ||
| JPWO2020234781A5 (enExample) | ||
| JP6420923B1 (ja) | 医薬 | |
| CN106507666A9 (zh) | 1，3‑丙二磺酸或其药学上可接受的盐用于治疗肉样瘤病的用途 | |
| CA2469702A1 (en) | Darifenacin for use in the treatment of urgency induced by overactive bladder | |
| JPWO2022009163A5 (enExample) | ||
| TW200501967A (en) | Nemorubicin for use in the preparation of a medicament for liver disease | |
| Buyse et al. | TO 3 SNT-MC17/idebenone in Duchenne muscular dystrophy: long-term blinded controlled preclinical study in the mdx mouse followed by a 12 month double-blind randomized controlled trial in humans | |
| US20030162769A1 (en) | Composition and method for treating vulvodynia | |
| KR20150017355A (ko) | 뇌 전이 치료를 위한 전뇌 방사선 요법과 병용하는 벨리파립 |